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Background: We describe four cases of primary lacrimal adenoid cystic carcinoma (ACC) treated with neoadjuvant
intra-arterial chemotherapy (NAIC).
Methods: The outcomes and complications of NAIC were reviewed. Several treatment-related local and/or systemic
complications were noted.
Results: One patient experienced ipsilateral eyelid and eyeball necrosis and permanent facial palsy; the second
patient developed ipsilateral facial swelling and jaw claudication; and the third patient had febrile neutropenia,
cellulitis, and phlebitis. These three patients underwent total exenteration. The fourth patient experienced
neutropenia and thrombocytopenia and underwent tumour removal without exenteration. All patients were
followed for more than 4 years and were alive at the last follow-up.
Conclusion: Neoadjuvant intra-arterial chemotherapy may be an alternative treatment that will improve the survival
rate of ACC. However, careful and close observation is needed to minimise the risk of side effects. Further
investigations are needed to justify the use of chemotherapy-related treatments and the associated costs.
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Primary lacrimal adenoid cystic carcinoma (ACC) is a
rare, aggressive, malignant epithelial cancer with re-
ported survival rates of less than 50% at 5 years and
20% at 10 years [1,2]. In our institution, the Severance
Hospital, we usually perform total exenteration, neigh-
bouring bone resection, adjuvant radiation therapy, and
systemic chemotherapy in patients with ACC. Such ag-
gressive treatments should be considered due to the
poor prognosis of ACC [1,2]. Advances in imaging
technology have enabled the detection of this cancer at
an early stage. Moreover, supplementary treatments,
such as radiation therapy and chemotherapy, also play
an important role in enhancing survival rates by pre-
venting recurrence and metastasis. In 1998, Meldrum
et al. [3] first introduced the concept of neoadjuvant* Correspondence: sylee@yuhs.ac
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unless otherwise stated.chemotherapy in the ophthalmological field through the
treatment of two patients with advanced ACC of the lac-
rimal gland. The two patients had survived for 7.5 and
9.5 years at the last follow-up, thereby establishing the
use of neoadjuvant chemotherapy in the treatment of
ACC as a new paradigm. In 2006, Tse et al. [4] reported
nine patients in whom neoadjuvant chemotherapy was
used to treat ACC successfully, emphasising the useful-
ness of this treatment for local disease control and the
enhancement of disease-free survival.
We performed neoadjuvant intra-arterial chemotherapy
(NAIC) using the modified methods of Meldrum et al. [3]
and Tse et al. [4] for four patients who visited our institu-
tion between February 2007 and May 2009. The aim of
the present study was to report the complications related
to NAIC. In addition, we also discuss an interventional
method in terms of selecting an artery for NAIC that has
not been reported previously in the literature.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients
This study was a non-comparative, consecutive case
series. We conducted chart reviews of four survivors who
visited the Severance Hospital, Yonsei University College
of Medicine, Seoul, South Korea, between February 2007
and May 2009. All patients were diagnosed with primary
lacrimal ACC and underwent NAIC. The patients had
no intracranial infiltration or distant metastasis at the
initial presentation. The tumour stage in all patients
was T4N0M0 according to the staging criteria of the
American Joint Committee on Cancer [5]. All patients
were subjected to incisional biopsy to confirm the histo-
logical diagnosis. All patients agreed to the NAIC
following full discussion of the poor prognosis of the
disease, current treatment strategy, complications re-
lated to NAIC, and the uncertainty regarding the effect-
iveness of the treatment.
Demographics, clinical presentations, radiological im-
aging, and histopathological data were investigated. We
reviewed the radiological images during the NAIC, the
local and systemic complications after treatment, and
the presence of local recurrence and distal metastasis.
The status at the last follow-up was also evaluated. Ap-
proval to conduct this retrospective study was obtained
from the Institutional Review Board of Severance Hos-
pital of Yonsei University.Neoadjuvant intra-arterial chemotherapy technique
Bilateral internal and external carotid angiography was
performed through a transfemoral approach with ad-
equate precautions, using a 4 F or 5 F Headhunter diag-
nostic catheter (COOK MEDICAL INC., Bloomington,
IN, USA). The primary feeding artery that stains the lac-
rimal gland (usually a branch of the lacrimal artery) was
identified. The lacrimal artery can branch out from the
ophthalmic artery (a branch of the internal carotid
artery (ICA)) or from the middle meningeal artery (a
branch of the external carotid artery (ECA)) as the
meningo-lacrimal variant [6-8]. After defining the arter-
ial anatomy, the diagnostic catheter was replaced for a
5 F Envoy® Guiding Catheter (Cordis Corporation,
Miami Lakes, FL, USA). Subsequently, a Prowler® 14
microcatheter (Cordis Corporation) was coaxially intro-
duced through the guiding catheter to attempt superse-
lective cannulation of the artery feeding the lacrimal
gland. The chemotherapeutic agent was infused through
the microcatheter. During the chemoinfusion, intermittent
fluoroscopic monitoring was done to ascertain adequate
catheter position. We administered up to 3000 units of
heparin intravenously during the procedure to prevent
catheter-related thrombotic complications. Post-infusion
angiography was performed to exclude any complications.In our practice, NAIC needs 3 days of hospitalisation.
On the first day of admission, intra-arterial chemoinfu-
sion of cisplatin is done using the aforementioned tech-
nique; 60–80 mg/ m2 of cisplatin is diluted in 500 ml of
normal saline solution and injected over 1 hour. Doxo-
rubicin (20–25 mg/m2) is given intravenously for 3 days
from the first day of hospitalisation. Thus, each chemo-
therapy cycle lasts 3 days, and the interval between two
cycles is 21 days. A total of three cycles is regarded as
completion of the regimen. Patients are followed up
with computed tomography (CT) scans to assess the re-
sponse. Orbital exenteration is done 3–4 weeks after the
last NAIC cycle. Surgery is followed by radiation ther-
apy (RT; dose, 6000 cGy) administered using a standard
daily fraction protocol.
Results
Between February 2007 and May 2009, a total of four
patients with primary lacrimal ACC underwent NAIC.
Patient demographics, outcomes, and the complications
of NAIC are summarised in Table 1.
Patient 1
A 35-year-old pregnant woman presented with a 3-month
history of progressive right proptosis. Exophthalmometry
showed a 2-mm proptosis in the right eye. She was preg-
nant and hence denied any further investigations. At a
later follow-up, 1 month from childbirth, a right-sided
proptosis of approximately 4 mm was identified and it
was accompanied by ocular pain and conjunctival hyper-
aemia. Her vision was 20/20 in both eyes, and her intraoc-
ular pressure was 17/15 mmHg.
During NAIC, the ECA angiogram did not show tumour
vascular staining or identified flow towards the orbit. The
ICA angiogram showed the main blood flow supply to the
orbit via the ophthalmic arterial branch (Figure 1). We
performed NAIC through the ophthalmic artery after
obtaining the patient’s consent because total exenteration
after completing the NAIC had already been planned. The
Prowler 14 microcatheter was positioned at the proximal
end of the ophthalmic artery, which supplied the orbit, in-
cluding the lacrimal grand. Contrast injections through
the microcatheter did not show significant reflux into the
cerebral circulation. Cisplatin (80 mg/m2) was infused
with no complications. Systemic doxorubicin (25 mg/m2)
was administered intravenously.
One week after NAIC, necrosis of the right upper eyelid
was noted, and the patient complained of hypoaesthesia on
the forehead. Gradually, the entire eyelid necrosed and the
eyeball was exposed (Figure 2). Systemic complications,
such as gingivitis, oral ulceration, alopecia, general weak-
ness, and neutropenia (absolute neutrophil count of < 1500)
were noted. The second NAIC angiogram, which was
obtained after 6 weeks, showed hypotrophy of the right






Location NAIC Surgery Complications Recurrence/
metastasis
Outcome
CASE 1 35/F Cribriform-like ACC Right orbit 2 cycles Total exenteration Ipsilateral eyelid and eyeball
necrosis, permanent facial palsy
No Survival
CASE 2 54/F Tubular pattern ACC Right orbit 3 cycles Total exenteration Facial swelling and tenderness,
difficulties in chewing
No Survival
CASE 3 45/F Cribriform-like ACC Right orbit 1 cycle Total exenteration Febrile neutropenia, cellulitis No Survival





F, female; M, male; ACC, adenoid cystic carcinoma; NAIC, neoadjuvant intra-arterial chemotherapy.
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orbit from the middle meningeal artery (MMA), and a
distal maxillary artery from the ECA. The microcatheter
was positioned in the distal portion of the main ECA
trunk, and cisplatin was injected.
Four days later, right facial palsy was observed. Because
of the local and systemic complications, the third cycle of
NAIC was cancelled. Total exenteration was performed,
and RT (6000 cGy) was performed 3 months later. Right
facial palsy remained after the total exenteration. At the
69-month follow-up, the patient was disease-free.
Patient 2
A 54-year-old woman presented with a 1-month history
of right eye vision loss with progressive proptosis. Her
visual acuity at the first visit was 20/400 in the right eye
and 20/20 in the left eye. Her intraocular pressure was
19/19 mmHg. Right proptosis of 6 mm was noted.
A CT scan showed a solid tissue mass with an irregu-
lar margin in the right orbit, with direct invasion into
the adjacent bony orbit. The tubular pattern typical of
ACC was confirmed on incisional biopsy.Figure 1 Patient 1 (35-year-old woman). (a) Lateral intracarotid angiogr
artery. (b) The extra-carotid angiogram does not show tumour vascular sta
internal carotid artery; MMA, middle meningeal artery.At angiography, the tumoural staining was seen during
the ECA injection (Figure 3). The microcatheter was
inserted into the distal portion of the main trunk of the
ECA, just proximal to the MMA, and cisplatin (80 mg/m2)
was infused for 1 hour. Doxorubicin (25 mg/m2) was
injected intravenously. Five days after NAIC, the left
thumb of the patient was pricked by a thorn; she subse-
quently developed pain, swelling, fever, and general weak-
ness. Her body temperature was 39°C, and her absolute
neutrophil count was 530. The patient was diagnosed
with febrile neutropenia, cellulitis, and phlebitis and re-
quired hospitalisation (Figure 4a). Erythematous blisters
of various sizes were found on her forehead, abdomen,
and tibia (Figure 4b). On consultation with the Derma-
tology Department, the blisters were determined to be
viral in origin. Aciclovir cream was applied, and the le-
sions were controlled.
Although viral infection during the immunosuppres-
sion phase of chemotherapy is not inherent to the intra-
arterial route of delivery [9], we reduced the dose of
cisplatin from 80 to 60 mg/m2 due to the systemic com-
plication. The dose of doxorubicin was also reducedam shows the lacrimal artery (LA) originating from the ophthalmic
ining or flow towards the orbit. ECA, external carotid artery; ICA,
Figure 2 Patient 1 (35-year-old woman). Eyelid and eyeball necrosis as local complications of intra-arterial chemotherapy, resulting from the
selection of the internal carotid artery. Photograph was taken 1 week (a), 2 weeks (b), and 1 month (c) after neoadjuvant
intra-arterial chemotherapy.
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cycles were performed. All three cycles of the NAIC
regimen were completed in this patient, as originally
planned.
Approximately 5 weeks later, total exenteration was
performed. At the same time, bony erosion of the super-
ior and lateral orbital rim was noted, and adjacent bone
was removed using a rongeur. RT was initiated 6 weeks
after surgery. No local recurrence or distal metastasis
was observed over the next 59 months.Figure 3 Patient 2 (54-year-old woman). Tumour staining (arrowheads)
meningeal artery, which originated from the external carotid artery (ECA). TPatient 3
A 45-year-old woman presented with a 1-year history of
eyelid swelling. The discomfort and lid oedema had ag-
gravated over the last 3 months. At the time of presenta-
tion, visual acuity was 20/25 in both eyes, and the
intraocular pressure was 16/16 mmHg.
On physical examination, a hard, immovable mass was
palpable in the right superotemporal area. A CT scan
showed an ill-defined, soft tissue mass (Figure 5a). At
the incisional biopsy, an ACC of cribriform type waswas seen primarily from the lacrimal branch of the right middle
his staining enabled selection of an artery from the ECA branches.
Figure 4 Patient 2 (54-year-old woman). (a): Cellulitis of the thumb. (b) Viral blister on the abdomen due to neutropenia as a
systemic complication.
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was injected into the internal maxillary artery proximal
to the MMA. Doxorubicin (25 mg/m2) was administered
intravenously.
Three days after NAIC, the patient complained of
right facial pain, swelling, and discomfort on opening
the mouth. Erythema was noted on the right cheek and
neck. We infused dexamethasone (10 mg) intravenously,
and an ice bag was applied. The erythema resolved. A
follow-up CT obtained after 3 weeks showed that the size
of the tumour had decreased from 3 to 2.3 cm (Figure 5b).
However, the patient did not want to continue the NAIC;
therefore, we could not complete the full NAIC regimen.
After 1 month, total exenteration of the right orbit was
performed. Removal of the lateral zygomatic bone wasperformed because of cancer invasion of the lateral orbital
rim. In accordance with the therapeutic plan, postopera-
tive irradiation (6000 cGy) was performed. We followed
the patient for 48 months. At the last visit, the right infer-
ior orbital rim showed increased intensity on the magnetic
resonance imaging scan, and the patient is currently being
followed up closely.
Patient 4
A 75-year-old man presented with a 3-month history of
right eye pain and proptosis. He was diagnosed with
ACC, and total exenteration was recommended at an-
other hospital. He did not consent to this radical treat-
ment. At the first visit to our hospital, his visual acuity
was 20/25 in the right eye and 20/20 in the left eye. His
Figure 5 Patient 3 (45-year-old woman). (a): Computed tomography (CT) scan taken before neoadjuvant intra-arterial chemotherapy (NAIC)
and (b) CT scan after NAIC. Note the reduction in tumour size.
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eye proptosis was noted.
A CT scan (Figure 6a) showed a soft tissue mass in the
superolateral right orbit. NAIC was performed as dis-
cussed earlier. An angiogram showed 56% vascular sten-
osis of the ICA. We selected the distal main trunk of the
ECA just proximal to the MMA for NAIC, and cisplatin
(80 mg/m2) and systemic doxorubicin (25 mg/m2) were
administered.
All three cycles of the NAIC regimen were completed,
and definite size reduction was observed after the treat-
ment (Figure 6b). Specific local complications related to
NAIC were not encountered, and mild decreases in
white blood cell and platelet counts were observed after
the second NAIC cycle.
After completion of the NAIC regimen, the patient
underwent mass removal with adjacent bone resection
(Figure 6c). External RT (6300 cGy) was performed
1 month after surgery. His visual acuity during the
follow-up period was 20/30 in the right eye and 20/20
in the left eye. Proptosis was not observed on perform-
ing exophthalmometry.
After 54 months from treatment, there was local re-
currence of the tumour for which exenteration was
recommended.
Discussion
Tse et al. [4] recently reported that the cumulative 5-year
ACC-specific death rate was 57.1% in a conventional treat-
ment group, but only 16.7% in an intra-arterial chemother-
apy treatment group. The cumulative 5-year recurrence
rate was 71.4% in the conventional group and 23.8% in the
chemotherapy group, emphasising the usefulness of intra-
arterial chemotherapy in local disease control and inimproving overall disease-free survival. Because ACC is ex-
tremely rare and has a poor prognosis, these results raise
the possibility of using intra-arterial chemotherapy in the
treatment of this disease. However, to date, few reports de-
tailing the use of intra-arterial chemotherapy for ACC have
been published [3,4]. The effectiveness of most therapies
for ACC is judged on the basis of retrospective case reports
or on expert opinion because of the rarity of the condition;
therefore, complications related to introducing new thera-
peutic modalities are worth noting. We have thus reported
the complications that we experienced during intra-arterial
chemotherapy and have further discussed interventional
methods resulting in local complications.
With respect to selecting an artery for chemotherapy,
Meldrum et al. [3] and Tse et al. [4] recommended using
the ECA to inject a chemotherapeutic agent for treat-
ment of lacrimal gland tumours. The authors explained
that the ECA was the preferred artery because of con-
cerns that the chemotherapeutic agents could be deliv-
ered into the cerebral circulation when injecting into
arterial feeders originating from the ICA [4]. However,
in our experience, the feeding vessel to the tumour may
not be always obvious on the ECA angiogram. Patient 1
had main lacrimal feeders from the ophthalmic artery of
the internal carotid system instead of the ECA. Because
of this anatomical disposition and because exenteration
of the eye had already been planned, and further because
contrast injections through the microcatheter did not
show reflux into the cerebral circulation, we opted to in-
fuse through the ICA feeder. Understanding the anatom-
ical variations of the blood vessels that supply the lacrimal
gland is required prior to performing intra-arterial selec-
tion. The lacrimal artery can branch out from the ophthal-
mic artery originating from the ICA, but it can also
Figure 6 Patient 4 (75-year-old man). (a) Preoperative computed tomography (CT) scan. (b) CT scan obtained after neoadjuvant intra-arterial
chemotherapy (NAIC). Note the reduction in tumour size after NAIC. (c) CT scan obtained after tumour resection with adjacent bone removal.
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Moreover, it can receive a blood supply from both [6-8].
The orbit can receive a collateral supply from the distal
maxillary artery and the infraorbital, sphenopalatine, and
anterior deep temporal arteries. Because the ophthalmic
artery was selected in patient 1, necrosis occurred in the
eyeball as well as in the eyelid that received the blood sup-
ply from this branch. The toxicity of the antitumour agent
is suggested as the cause of the eyelid and eyeball necrosis
in this case. Although in this case there were no complica-
tions related to the chemotherapeutic agent being deliv-
ered into the cerebral circulation, the risk of injection into
the cerebral circulation when selecting the ICA should be
kept in mind.In the present study, all patients survived until the last
follow-up. These outcomes are in accordance with the
successful results pertaining to local disease control and
overall disease-free survival that have been reported previ-
ously [4]. Imaging technology and supplementary treat-
ments, including intra-arterial chemotherapy, are expected
to play a positive role not only in enhancing survival rates,
but also in preventing orbital exenteration. Several recent
reports have stated that good survival is achieved by re-
moving only the tumour and using plaque radiotherapy,
without performing exenteration [10,11]. These authors re-
ported that conservative treatment was possible because
radiation could be used for residual cancer cells and that
this treatment would be especially useful for small children
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patient who underwent only tumour resection and not
exenteration (patient 4) showed tumour recurrence at
the last follow-up. The tumour cells can exit the orbit
along either the lacrimal nerve or the blood vessel from
the time of diagnosis because of the micrometastasis
and perineural invasion characteristics of ACC. To con-
clude that intra-arterial chemotherapy might prevent
this type of local and possibly metastatic aggressiveness,
further study is needed.
Conclusion
In conclusion, NAIC may increase the survival rate of pa-
tients with ACC and may represent a new treatment
option for preservation of the eye in such cases. However,
to decrease treatment-related complications and ensure
completion of the three-cycle protocol, close observation
through proper follow-up after treatment and appropriate
management of adverse effects are necessary.
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